Freeline is a clinical-stage biotechnology company developing AAV gene therapies. We are dedicated to improving patient lives through innovative, one-time treatments for chronic debilitating diseases. We use our proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. We are advancing clinical programs in Fabry disease and Gaucher disease type 1. Freeline is headquartered in the UK and has operations in the United States.